Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1194422

	registered interest
	date	11/05/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Zuhlke Engineering: Contact Tracing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the value was of the contract awarded to Zuhlke Engineering for the development of the NHS covid-19 contact tracing app.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	45256
	answer	answer is ministerial correction date of answer 18/05/2020 answer text <p>Zühlke Engineering has been awarded contracts of £895,000 for mobile development, and £812,000 for build assurance and system integration. They have also been awarded a contract of £3.813 million (with extension options, if needed) to support the app once launched.</p><p> </p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 18/05/2020 15:43:06 answering member 1481 label Biography information for Ms Nadine Dorries
	tabling member	4382 label Biography information for Daniel Zeichner

1580222

	registered interest
	date	24/01/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access: Life Sciences
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Secretary of State for Business, Energy, and Industrial Strategy on the impact of the Voluntary Scheme for Branded Medicines Pricing Access on the life sciences sector.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	131295
	answer	answer is ministerial correction date of answer 30/01/2023 answer text <p>Ministers in the Department engage regularly with their Ministerial counterparts on a range of issues, including those relating to the Voluntary Scheme for Branded Medicines Pricing Access.</p> answering member constituency Colchester answering member printed Will Quince question first answered 30/01/2023 16:53:19 answering member 4423 label Biography information for Will Quince
	tabling member	4382 label Biography information for Daniel Zeichner

1608018

	registered interest
	date	27/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access: Disclosure of Information
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s ongoing VPAS pre-negotiation workshops, if he will publish the (a) minutes and (b) attendees of those workshops.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	174320
	answer	answer is ministerial correction date of answer 30/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme for branded medicines pricing and access (VPAS) upon the different organisations represented and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 VPAS. In order to facilitate a transparent and candid discussion, participants agreed that all contributions and resulting outputs would be kept confidential to those who attended.</p><p>The following organisations were invited to the workshops:</p><p>Industry bodies (including representatives of their member companies):</p><p>- Association of the British Pharmaceutical Industry;</p><p>- British Generic Manufacturers Association;</p><p>- Ethical Medicines Industry Group;</p><p>- BioIndustry Association.</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52;</p><p>- The Blood Cancer Alliance;</p><p>- The Charity Medicines Access Coalition;</p><p>- National Voices;</p><p>- The Patients Association;</p><p>- Alzheimer’s Research UK;</p><p>- Anthony Nolan;</p><p>- Cystic Fibrosis Trust;</p><p>- Genetic Alliance UK;</p><p>- The Association of Medical Research Charities;</p><p>- Breast Cancer Now;</p><p>- Myeloma UK;</p><p>- Office of Health Economics;</p><p>- King’s Fund;</p><p>- NHS Confederation.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 174321 question first answered 30/03/2023 15:18:28 answering member 4423 label Biography information for Will Quince
	tabling member	4382 label Biography information for Daniel Zeichner

1608020

	registered interest
	date	27/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access: Disclosure of Information
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s ongoing VPAS pre-negotiation workshops, whether he plans to make the outputs of those discussions publicly available.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	174321
	answer	answer is ministerial correction date of answer 30/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme for branded medicines pricing and access (VPAS) upon the different organisations represented and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 VPAS. In order to facilitate a transparent and candid discussion, participants agreed that all contributions and resulting outputs would be kept confidential to those who attended.</p><p>The following organisations were invited to the workshops:</p><p>Industry bodies (including representatives of their member companies):</p><p>- Association of the British Pharmaceutical Industry;</p><p>- British Generic Manufacturers Association;</p><p>- Ethical Medicines Industry Group;</p><p>- BioIndustry Association.</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52;</p><p>- The Blood Cancer Alliance;</p><p>- The Charity Medicines Access Coalition;</p><p>- National Voices;</p><p>- The Patients Association;</p><p>- Alzheimer’s Research UK;</p><p>- Anthony Nolan;</p><p>- Cystic Fibrosis Trust;</p><p>- Genetic Alliance UK;</p><p>- The Association of Medical Research Charities;</p><p>- Breast Cancer Now;</p><p>- Myeloma UK;</p><p>- Office of Health Economics;</p><p>- King’s Fund;</p><p>- NHS Confederation.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 174320 question first answered 30/03/2023 15:18:28 answering member 4423 label Biography information for Will Quince
	tabling member	4382 label Biography information for Daniel Zeichner

1139442

	registered interest
	date	16/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the 2019 Voluntary Scheme for Branded Medicines Pricing and Access, how many opportunities there have been for pharmaceutical industry trade bodies to input into NHS England’s commercial framework; and what steps the Government is taking to secure the participation of industry trade bodies.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	277757
	answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, are developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</p><p>The commercial framework will support an integrated pricing and access process and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</p><p>In preparation for public consultation in the coming months, NHS England and NHS Improvement are actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 15:46:12 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4382 label Biography information for Daniel Zeichner

1580218

	registered interest
	date	24/01/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of changes to the voluntary scheme for branded medicines pricing and access rebate rate on (a) investment in late-stage clinical trials and (b) patient access to new medicines.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	131294
	answer	answer is ministerial correction date of answer 30/01/2023 answer text <p>We have not made a specific assessment of the potential impact of changes to 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) payment percentages on late-stage clinical trials and access to new medicines. An assessment relevant to these issues was published in December 2022 on the impact of changes to payment percentages in the associated Statutory Scheme for Branded Medicines.</p><p>Changes to the VPAS payment percentages reflect the scheme working as intended to adjust for increased sales of branded medicines to the National Health Service and are below the rate projected when the Scheme was agreed with industry in 2018.</p><p>The NHS has delivered a record number of access agreements since VPAS was agreed including many world and European-first agreements. The NHS has delivered world-leading uptake of some of the most important cancer and rare disease drugs, while also agreeing deals for a number of new cell and gene therapies.</p> answering member constituency Colchester answering member printed Will Quince question first answered 30/01/2023 16:47:19 answering member 4423 label Biography information for Will Quince
	tabling member	4382 label Biography information for Daniel Zeichner

1604911

	registered interest
	date	16/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish (a) the minutes from and (b) a list of attendees at the workshops his Department has been running ahead of negotiations on a new Voluntary Scheme for Branded Medicines Pricing and Access.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	167135
	answer	answer is ministerial correction date of answer 23/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme upon the different organisations represented, and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 voluntary scheme for branded medicines pricing and access. In order to facilitate a transparent and candid discussion, participants agreed that all contributions would be kept confidential to those who attended.</p><p>The following external organisations were invited to the workshops:</p><p>Industry bodies:</p><p>- Association of the British Pharmaceutical Industry</p><p>- British Generic Manufacturers Association</p><p>- Ethical Medicines Industry Group</p><p>- BioIndustry Association</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52</p><p>- The Blood Cancer Alliance</p><p>- The Charity Medicines Access Coalition</p><p>- National Voices</p><p>- The Patients Association</p><p>- Alzheimer’s Research UK</p><p>- Anthony Nolan</p><p>- Cystic Fibrosis Trust</p><p>- Genetic Alliance UK</p><p>- The Association of Medical Research Charities</p><p>- Breast Cancer Now</p><p>- Myeloma UK</p><p>- Office of Health Economics</p><p>- King’s Fund</p><p>- NHS Confederation</p><p> </p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 167136 question first answered 23/03/2023 16:20:08 answering member 4423 label Biography information for Will Quince
	tabling member	4382 label Biography information for Daniel Zeichner

1604912

	registered interest
	date	16/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to publish information about the outcomes from the workshops that his Department has been running ahead of negotiations on a new Voluntary Scheme for Branded Medicines Pricing and Access.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	167136
	answer	answer is ministerial correction date of answer 23/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme upon the different organisations represented, and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 voluntary scheme for branded medicines pricing and access. In order to facilitate a transparent and candid discussion, participants agreed that all contributions would be kept confidential to those who attended.</p><p>The following external organisations were invited to the workshops:</p><p>Industry bodies:</p><p>- Association of the British Pharmaceutical Industry</p><p>- British Generic Manufacturers Association</p><p>- Ethical Medicines Industry Group</p><p>- BioIndustry Association</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52</p><p>- The Blood Cancer Alliance</p><p>- The Charity Medicines Access Coalition</p><p>- National Voices</p><p>- The Patients Association</p><p>- Alzheimer’s Research UK</p><p>- Anthony Nolan</p><p>- Cystic Fibrosis Trust</p><p>- Genetic Alliance UK</p><p>- The Association of Medical Research Charities</p><p>- Breast Cancer Now</p><p>- Myeloma UK</p><p>- Office of Health Economics</p><p>- King’s Fund</p><p>- NHS Confederation</p><p> </p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 167135 question first answered 23/03/2023 16:20:08 answering member 4423 label Biography information for Will Quince
	tabling member	4382 label Biography information for Daniel Zeichner

1020233

	registered interest
	date	05/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will place in the Library (a) all instances where the Joint Committee on Vaccination and Immunisation has recommended a change to a vaccination programme that would be likely to result in an increase in disease incidence, (b) whether those recommendations were accepted by Ministers and (c) the subsequent changes in disease incidence following those decisions.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	199422
	answer	answer is ministerial correction date of answer 12/12/2018 answer text <p>The information is not held in the format requested and could only be obtained at disproportionate cost.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/12/2018 14:55:49 answering member 4067 label Biography information for Steve Brine
	tabling member	4382 label Biography information for Daniel Zeichner

1055992

	registered interest
	date	06/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his policy paper Tackling antimicrobial resistance 2019 to 2024: the UK's 5-year national action plan, if he will amend the code of practice for the Joint Committee on Vaccination and Immunisation to require that Committee to assess the effect on the level of anti-microbial resistance of (a) a new, (b) major changes to and (c) the discontinuation of an immunisation programme.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	217595
	answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI’s) terms of reference is to advise the United Kingdom health departments on immunisations for the prevention of infections and/or disease following due consideration of the evidence on the burden of disease, on vaccine safety and efficacy and on the impact and cost effectiveness of immunisation strategies.</p><p>JCVI is aware that vaccination has an important role in controlling antimicrobial resistance. As most resistant infections are healthcare associated, the new JCVI Healthcare Associated Infections Working Group, set up to review and provide preliminary advice to JCVI on the potential use of appropriate vaccines in the UK, will help to address this issue.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/02/2019 17:20:40 answering member 4067 label Biography information for Steve Brine
	tabling member	4382 label Biography information for Daniel Zeichner